FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean‐Baptiste Bachet, Gilles Breysacher et al.|New England Journal of Medicine|2018Cited by 2.8k
An update on treatment options for pancreatic adenocarcinomaAurélien Lambert, Thierry Conroy, Lilian Schwarz et al.|Therapeutic Advances in Medical Oncology|2019Cited by 211
Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05Valérie Boige, Pierre Laurent‐Puig, Jean Mendiboure et al.|Journal of Clinical Oncology|2010Cited by 169
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trialOlivier Mir, Étienne Minvielle, Marie Ferrua et al.|Nature Medicine|2022Cited by 138
Molecular targeted therapy of <i>BRAF</i> -mutant colorectal cancerMichel Ducreux, Maximiliano Gelli, Ali N. Chamseddine et al.|Therapeutic Advances in Medical Oncology|2019Cited by 102